Ocular Therapeutix Company Profile (NASDAQ:OCUL)

About Ocular Therapeutix (NASDAQ:OCUL)

Ocular Therapeutix logoOcular Therapeutix, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies for diseases and conditions of the eye using its hydrogel platform technology. The Company's bioresorbable hydrogel based product candidates are designed to provide sustained delivery of therapeutic agents to the eye. Its lead product candidates are DEXTENZA (dexamethasone insert), for the treatment of post-surgical ocular inflammation and pain, allergic conjunctivitis and dry eye disease, and OTX-TP, for the treatment of glaucoma and ocular hypertension, which are extended-delivery, drug-eluting inserts that are placed into the canaliculus through a natural opening called the punctum located in the inner portion of the eyelid near the nose. It also has an intravitreal hydrogel depot, which is in preclinical development for the treatment of diseases and conditions of the back of the eye, including wet age-related macular degeneration (wet AMD).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Equipment, Supplies & Distribution - NEC
  • Sub-Industry: N/A
  • Symbol: NASDAQ:OCUL
  • CUSIP: N/A
  • Web: www.ocutx.com
Capitalization:
  • Market Cap: $170.69 million
  • Outstanding Shares: 29,056,000
Average Prices:
  • 50 Day Moving Avg: $6.57
  • 200 Day Moving Avg: $8.62
  • 52 Week Range: $4.82 - $11.91
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.70
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $1.9 million
  • Price / Sales: 88.70
  • Book Value: $1.65 per share
  • Price / Book: 3.52
Profitability:
  • EBIDTA: ($54,640,000.00)
  • Net Margins: -3,005.52%
  • Return on Equity: -101.03%
  • Return on Assets: -69.76%
Debt:
  • Debt-to-Equity Ratio: 0.32%
  • Current Ratio: 5.20%
  • Quick Ratio: 5.20%
Misc:
  • Average Volume: 1.25 million shs.
  • Beta: 1.59
  • Short Ratio: 3.03
 

Frequently Asked Questions for Ocular Therapeutix (NASDAQ:OCUL)

What is Ocular Therapeutix's stock symbol?

Ocular Therapeutix trades on the NASDAQ under the ticker symbol "OCUL."

How were Ocular Therapeutix's earnings last quarter?

Ocular Therapeutix, Inc. (NASDAQ:OCUL) issued its quarterly earnings data on Tuesday, August, 8th. The company reported ($0.64) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.59) by $0.05. The business had revenue of $0.40 million for the quarter, compared to analysts' expectations of $0.51 million. Ocular Therapeutix had a negative return on equity of 101.03% and a negative net margin of 3,005.52%. The company's revenue for the quarter was up .0% on a year-over-year basis. During the same period last year, the business earned ($0.46) earnings per share. View Ocular Therapeutix's Earnings History.

When will Ocular Therapeutix make its next earnings announcement?

Ocular Therapeutix is scheduled to release their next quarterly earnings announcement on Tuesday, November, 7th 2017. View Earnings Estimates for Ocular Therapeutix.

Where is Ocular Therapeutix's stock going? Where will Ocular Therapeutix's stock price be in 2017?

6 brokerages have issued 1-year target prices for Ocular Therapeutix's shares. Their predictions range from $8.00 to $60.00. On average, they anticipate Ocular Therapeutix's share price to reach $24.00 in the next year. View Analyst Ratings for Ocular Therapeutix.

What are analysts saying about Ocular Therapeutix stock?

Here are some recent quotes from research analysts about Ocular Therapeutix stock:

  • 1. According to Zacks Investment Research, "Ocular Therapeutix, Inc. is a biopharmaceutical company. It is focused on the development and commercialization of ophthalmic therapeutic products using its proprietary hydrogel technology to address unmet or underserved needs in ophthalmology. The Company develops and markets eye care products. Ocular Therapeutix, Inc. is headquartered in Bedford, Massachusetts. " (5/23/2017)
  • 2. Cantor Fitzgerald analysts commented, "We are initiating on Ocular Therapeutix with an Overweight rating and $35 Price target. We believe Ocular's portfolio of sustained release therapies have the potential to treat an array of ophthalmic conditions with significant unmet need. In focus, we view the upcoming FDA decision this year for lead developmental candidate DEXTENZA' in post-surgical ocular pain as a meaningful catalyst for the shares, and estimate that DEXTENZA could reach annual sales of $600 million at peak market penetration in 2023, with further growth to $900 million by 2030 for this indication alone in the U.S." (2/9/2017)

Who are some of Ocular Therapeutix's key competitors?

Who are Ocular Therapeutix's key executives?

Ocular Therapeutix's management team includes the folowing people:

  • Amarpreet Sawhney Ph.D., Executive Chairman of the Board
  • James Fortune, Interim Principal Financial Officer, Chief Operating Officer, Interim Princiapl Accounting Officer
  • George V. Migausky, Interim Chief Financial Officer
  • Eric P. Ankerud, Executive Vice President, Regulatory, Quality and Compliance
  • Andy Hurley, Chief Commercial Officer
  • Jonathan Talamo M.D., Chief Medical Officer
  • Jaswinder S. Chadha, Director
  • W. James O'Shea, Director
  • Jeffrey S. Heier M.D., Independent Director
  • Richard L. Lindstrom M.D., Independent Director

Who owns Ocular Therapeutix stock?

Ocular Therapeutix's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Versant Venture Management LLC (7.63%), Jennison Associates LLC (6.84%), SV Health Investors LLC (5.53%), FMR LLC (4.56%), Vanguard Group Inc. (3.12%) and Columbus Circle Investors (1.99%). Company insiders that own Ocular Therapeutix stock include Amarpreet Sawhney and James Fortune. View Institutional Ownership Trends for Ocular Therapeutix.

Who sold Ocular Therapeutix stock? Who is selling Ocular Therapeutix stock?

Ocular Therapeutix's stock was sold by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Columbus Circle Investors, Deltec Asset Management LLC, FMR LLC, JPMorgan Chase & Co., Edmond DE Rothschild Holding S.A., Wells Fargo & Company MN and NEXT Financial Group Inc. View Insider Buying and Selling for Ocular Therapeutix.

Who bought Ocular Therapeutix stock? Who is buying Ocular Therapeutix stock?

Ocular Therapeutix's stock was acquired by a variety of institutional investors in the last quarter, including Cowen Inc., State Street Corp, Northern Trust Corp, Parametric Portfolio Associates LLC, Neuberger Berman Group LLC, State of Wisconsin Investment Board, Alliancebernstein L.P. and Voya Investment Management LLC. View Insider Buying and Selling for Ocular Therapeutix.

How do I buy Ocular Therapeutix stock?

Shares of Ocular Therapeutix can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Ocular Therapeutix's stock price today?

One share of Ocular Therapeutix stock can currently be purchased for approximately $5.80.


MarketBeat Community Rating for Ocular Therapeutix (NASDAQ OCUL)
Community Ranking:  3.5 out of 5 (star star star half star)
Outperform Votes:  142 (Vote Outperform)
Underperform Votes:  59 (Vote Underperform)
Total Votes:  201
MarketBeat's community ratings are surveys of what our community members think about Ocular Therapeutix and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Ocular Therapeutix (NASDAQ:OCUL) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Hold Ratings, 4 Buy Ratings
Consensus Rating:Buy (Score: 2.67)
Consensus Price Target: $24.00 (313.79% upside)

Analysts' Ratings History for Ocular Therapeutix (NASDAQ:OCUL)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/10/2017BTIG ResearchReiterated RatingNeutralLowView Rating Details
8/9/2017HC WainwrightReiterated RatingBuy$10.00HighView Rating Details
7/14/2017Morgan StanleyReiterated RatingEqual Weight$16.00 -> $8.00LowView Rating Details
7/12/2017Cantor FitzgeraldLower Price TargetOverweight -> Overweight$35.00 -> $21.00HighView Rating Details
3/13/2017Cowen and CompanyReiterated RatingOutperform$60.00MediumView Rating Details
11/15/2016Royal Bank Of CanadaReiterated RatingOutperform$30.00 -> $32.00N/AView Rating Details
8/11/2016JMP SecuritiesInitiated CoverageOutperform$21.00 -> $5.84N/AView Rating Details
(Data available from 8/22/2015 forward)

Earnings

Earnings History for Ocular Therapeutix (NASDAQ:OCUL)
Earnings by Quarter for Ocular Therapeutix (NASDAQ:OCUL)
Earnings History by Quarter for Ocular Therapeutix (NASDAQ OCUL)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2017($0.54)N/AView Earnings Details
8/8/2017Q2 2017($0.59)($0.64)$0.51 million$0.40 millionViewListenView Earnings Details
5/5/2017Q1 2017($0.48)($0.58)$0.51 million$0.48 millionViewN/AView Earnings Details
3/10/2017Q4 2016($0.45)($0.52)$0.48 million$0.51 millionViewN/AView Earnings Details
11/9/2016Q316($0.50)($0.39)$0.47 million$0.48 millionViewListenView Earnings Details
8/9/2016Q216($0.49)($0.46)$0.55 million$0.44 millionViewListenView Earnings Details
5/10/2016Q116($0.43)($0.44)$458.00 millionViewListenView Earnings Details
3/10/2016Q415($0.47)($0.43)$0.44 millionViewListenView Earnings Details
11/10/2015Q315($0.38)($0.47)$0.43 millionViewListenView Earnings Details
8/10/2015Q215($0.33)($0.45)$0.46 millionViewListenView Earnings Details
5/15/2015Q115($0.39)($0.35)$0.30 million$0.43 millionViewListenView Earnings Details
3/10/2015Q4($0.38)($0.37)$0.20 million$0.51 millionViewListenView Earnings Details
11/12/2014Q3 14($0.55)($0.48)$0.10 million$0.14 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Ocular Therapeutix (NASDAQ:OCUL)
Current Year EPS Consensus Estimate: $-2.26 EPS
Next Year EPS Consensus Estimate: $-2.15 EPS

Dividends

Dividend History for Ocular Therapeutix (NASDAQ:OCUL)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Ocular Therapeutix (NASDAQ:OCUL)
Insider Ownership Percentage: 26.10%
Institutional Ownership Percentage: 59.12%
Insider Trades by Quarter for Ocular Therapeutix (NASDAQ:OCUL)
Institutional Ownership by Quarter for Ocular Therapeutix (NASDAQ:OCUL)
Insider Trades by Quarter for Ocular Therapeutix (NASDAQ:OCUL)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/15/2016Amarpreet SawhneyInsiderBuy45,300$7.85$355,605.00View SEC Filing  
6/9/2016Amarpreet SawhneyCEOBuy10,000$6.70$67,000.00View SEC Filing  
11/17/2015Amarpreet SawhneyCEOBuy10,000$8.25$82,500.00View SEC Filing  
9/15/2015James FortuneCOOSell9,470$17.16$162,505.20View SEC Filing  
9/14/2015Amarpreet SawhneyCEOBuy15,000$16.50$247,500.00View SEC Filing  
6/15/2015Charles M WardenDirectorSell320,000$22.00$7,040,000.00View SEC Filing  
6/10/2015Charles M WardenDirectorSell427,000$22.00$9,394,000.00View SEC Filing  
6/10/2015Svlsf Iv, LlcMajor ShareholderSell1,119,000$22.00$24,618,000.00View SEC Filing  
7/30/2014Amarpreet SawhneyCEOBuy76,922$13.00$999,986.00View SEC Filing  
7/30/2014Svlsf Iv, LlcMajor ShareholderBuy715,380$13.00$9,299,940.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Ocular Therapeutix (NASDAQ:OCUL)
Latest Headlines for Ocular Therapeutix (NASDAQ:OCUL)
Source:
DateHeadline
businesswire.com logoBragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Ocular Therapeutix, Inc. (OCUL) and Encourages Investors with Losses to Contact ...
www.businesswire.com - August 22 at 1:22 AM
americanbankingnews.com logoAnalyzing Transenterix (TRXC) and Ocular Therapeutix (OCUL)
www.americanbankingnews.com - August 21 at 8:09 AM
finance.yahoo.com logoINVESTOR ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Ocular Therapeutix, Inc. (OCUL) and Lead Plaintiff Deadline: September 5, 2017
finance.yahoo.com - August 19 at 6:09 AM
finance.yahoo.com logoEQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Filed a Class Action Complaint on Behalf of Ocular Therapeutix, Inc. Shareholders and Lead Plaintiff Deadline is Set for September 5, 2017 – OCUL
finance.yahoo.com - August 19 at 6:09 AM
finance.yahoo.com logoDEADLINE REMINDER: Lundin Law PC Announces Securities Class Action Lawsuit against Ocular Therapeutix, Inc. and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - August 19 at 6:09 AM
finance.yahoo.com logoAPPROACHING DEADLINE: Khang & Khang LLP Announces a Securities Class Action Lawsuit against Ocular Therapeutix, Inc. and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - August 17 at 10:03 PM
finance.yahoo.com logoINVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Filed a Class Action Complaint on Behalf of Ocular Therapeutix, Inc. Shareholders and Lead Plaintiff Deadline is Set for September 5, 2017 – OCUL
finance.yahoo.com - August 17 at 5:01 PM
finance.yahoo.com logoEQUITY ALERT: Khang & Khang LLP Announces a Securities Class Action Lawsuit against Ocular Therapeutix, Inc. and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - August 17 at 5:01 PM
finance.yahoo.com logoINVESTOR ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Ocular Therapeutix, Inc. (OCUL) and Lead Plaintiff Deadline - September 5, 2017
finance.yahoo.com - August 17 at 5:01 PM
finance.yahoo.com logoThe Klein Law Firm Reminds Investors of a Class Action Filed on Behalf of Ocular Therapeutix, Inc. Shareholders and a Lead Plaintiff Deadline of September 5, 2017 (OCUL)
finance.yahoo.com - August 17 at 5:01 PM
finance.yahoo.com logoSHAREHOLDER REMINDER: Lundin Law PC Announces Securities Class Action Lawsuit against Ocular Therapeutix, Inc. and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - August 17 at 6:25 AM
businesswire.com logoOCULAR THERAPEUTIX ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50000 ... - Business Wire (press release)
www.businesswire.com - August 16 at 6:28 AM
finance.yahoo.com logoINVESTOR ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Ocular Therapeutix, Inc. (OCUL) and Lead Plaintiff Deadline - September 5, 2017
finance.yahoo.com - August 15 at 5:31 AM
finance.yahoo.com logoINVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Filed a Class Action Complaint on Behalf of Ocular Therapeutix, Inc. Shareholders and Lead Plaintiff Deadline is Set for September 5, 2017 - OCUL
finance.yahoo.com - August 15 at 5:31 AM
finance.yahoo.com logoUPCOMING DEADLINE: Lundin Law PC Announces Securities Class Action Lawsuit against Ocular Therapeutix, Inc. and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - August 15 at 5:31 AM
finance.yahoo.com logoSHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Has Filed a Class Action Complaint on Behalf of Ocular Therapeutix, Inc. Shareholders and Lead Plaintiff Deadline is Set for September 5, 2017 – OCUL
finance.yahoo.com - August 12 at 6:33 AM
finance.yahoo.com logoAPPROACHING DEADLINE: Lundin Law PC Announces Securities Class Action Lawsuit against Ocular Therapeutix, Inc. and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - August 12 at 6:32 AM
finance.yahoo.com logoEdited Transcript of OCUL earnings conference call or presentation 8-Aug-17 9:00pm GMT
finance.yahoo.com - August 12 at 6:32 AM
finance.yahoo.com logoINVESTOR ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Ocular Therapeutix, Inc. (OCUL) & Lead Plaintiff Deadline - September 5, 2017
finance.yahoo.com - August 12 at 6:32 AM
feeds.benzinga.com logoEQUITY ALERT UPDATE: Rosen Law Firm Announces Filing of Securities Class Action Against Ocular Therapeutix, Inc. - OCUL
feeds.benzinga.com - August 10 at 7:30 PM
finance.yahoo.com logoINVESTOR ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Ocular Therapeutix, Inc. (OCUL) & Lead Plaintiff Deadline - September 5, 2017
finance.yahoo.com - August 10 at 6:26 AM
finance.yahoo.com logoINVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors It Filed a Class Action Complaint on Behalf of Ocular Therapeutix, Inc. Shareholders and Lead Plaintiff Deadline is Set for September 5, 2017 - OCUL
finance.yahoo.com - August 10 at 6:26 AM
finance.yahoo.com logoOcular Therapeutix™ Reports Second Quarter 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - August 10 at 6:26 AM
finance.yahoo.com logoEQUITY ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Ocular Therapeutix, Inc. and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - August 10 at 6:26 AM
finance.yahoo.com logoIMPORTANT OCULAR THERAPEUTIX, INC. INVESTOR REMINDER: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the District of New Jersey against Ocular Therapeutix, Inc.
finance.yahoo.com - August 10 at 6:26 AM
finance.yahoo.com logoOcular Therapeutix reports 2Q loss
finance.yahoo.com - August 10 at 6:26 AM
finance.yahoo.com logoSHAREHOLDER ALERT: Khang & Khang LLP Announces a Securities Class Action Lawsuit against Ocular Therapeutix, Inc. and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - August 10 at 6:26 AM
americanbankingnews.com logoOcular Therapeutix, Inc. (NASDAQ:OCUL) Releases Quarterly Earnings Results, Misses Expectations By $0.05 EPS
www.americanbankingnews.com - August 9 at 9:20 PM
globenewswire.com logoSHAREHOLDER ALERT: SFMS Announces Filing of Securities Class Action Lawsuit Against Ocular Therapeutix, Inc. - GlobeNewswire (press release)
globenewswire.com - August 9 at 6:03 AM
businesswire.com logoOcular Therapeutix™ Reports Second Quarter 2017 Financial Results and Provides Corporate Update - Business Wire (press release)
www.businesswire.com - August 9 at 6:03 AM
globenewswire.com logoIMPORTANT OCULAR THERAPEUTIX, INC. INVESTOR REMINDER: Wolf Haldenstein Adler Freeman & Herz LLP ... - GlobeNewswire (press release)
globenewswire.com - August 9 at 6:03 AM
americanbankingnews.com logoOcular Therapeutix, Inc. (NASDAQ:OCUL) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - August 8 at 7:46 AM
finance.yahoo.com logoOCUL Investors Update: Hagens Berman Alerts Investors in Ocular Therapeutix, Inc. to Expanded Class Period in Pending Securities Class Action and Reminds Them of the September 5, 2017 Lead Plaintiff Deadline
finance.yahoo.com - August 8 at 3:32 AM
finance.yahoo.com logoIMPORTANT EQUITY ALERT: Khang & Khang LLP Announces a Securities Class Action Lawsuit against Ocular Therapeutix, Inc. and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - August 8 at 3:32 AM
feeds.benzinga.com logoSHAREHOLDER ALERT: SFMS Announces Filing of Securities Class Action Lawsuit Against Ocular Therapeutix, Inc.
feeds.benzinga.com - August 7 at 10:25 AM
americanbankingnews.com logoOcular Therapeutix, Inc. (OCUL) Downgraded to "Sell" at ValuEngine
www.americanbankingnews.com - August 6 at 10:02 AM
businesswire.com logoOcular Therapeutix™ Appoints Daniel Bollag, Ph.D., as Senior Vice President, Regulatory Affairs, Pharmacovigilance ... - Business Wire (press release)
www.businesswire.com - August 5 at 5:15 AM
finance.yahoo.com logo​Ocular Therapeutix replaces regulatory chief after FDA rejection
finance.yahoo.com - August 5 at 5:15 AM
finance.yahoo.com logoSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Ocular Therapeutix, Inc. of Class Action Lawsuit and Upcoming Deadline – OCUL
finance.yahoo.com - August 5 at 5:15 AM
finance.yahoo.com logoSHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Ocular Therapeutix, Inc. and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - August 5 at 5:15 AM
finance.yahoo.com logoINVESTOR ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Ocular Therapeutix, Inc. (OCUL) & Lead Plaintiff Deadline: September 5, 2017
finance.yahoo.com - August 4 at 6:34 AM
finance.yahoo.com logoIMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces a Securities Class Action Lawsuit against Ocular Therapeutix, Inc. and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - August 4 at 6:34 AM
finance.yahoo.com logoSHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders It Filed a Class Action Complaint on Behalf of Ocular Therapeutix, Inc. Shareholders and Lead Plaintiff Deadline is Set for September 5, 2017 - OCUL
finance.yahoo.com - August 4 at 6:34 AM
feeds.benzinga.com logoThe Klein Law Firm Notifies Investors of a Class Action Filed on Behalf of Ocular Therapeutix, Inc. Shareholders and a Lead Plaintiff Deadline of September 5, 2017 (OCUL)
feeds.benzinga.com - August 2 at 10:56 AM
reuters.com logoBRIEF-Ocular Therapeutix to eliminate 26 positions across organization
www.reuters.com - August 2 at 6:32 AM
finance.yahoo.com logoSafirstein Metcalf LLP Reminds Investors That A Class Action Has Been Filed Against Ocular Therapeutix, Inc. – OCUL
finance.yahoo.com - August 2 at 6:32 AM
finance.yahoo.com logoOcular Therapeutix™ Announces Antony Mattessich Assumes Role as Chief Executive Officer
finance.yahoo.com - August 2 at 6:32 AM
finance.yahoo.com logoINVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Ocular Therapeutix, Inc. and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - August 2 at 6:32 AM
finance.yahoo.com logoBedford’s Ocular Therapeutix turns to layoffs after FDA rejection
finance.yahoo.com - August 2 at 6:32 AM
finance.yahoo.com logoINVESTOR ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Ocular Therapeutix, Inc. (OCUL) & Lead Plaintiff Deadline: September 5, 2017
finance.yahoo.com - August 1 at 4:59 AM

Social

Chart

Ocular Therapeutix (OCUL) Chart for Tuesday, August, 22, 2017

This page was last updated on 8/22/2017 by MarketBeat.com Staff